Selexipag

BOSTON — Having pulmonary arterial hypertension plus a mental health comorbidity did not result in differing treatments or outcomes from those without this comorbidity, according to data presented at the CHEST Annual Meeting.

Health care professionals treating patients with pulmonary arterial hypertension recommend individualized dosing and titration of oral selexipag, according to a poster presented at the International Pulmonary Hypertension Conference.

NASHVILLE, Tenn. — Initiation of oral selexipag within 12 months of pulmonary arterial hypertension diagnosis may reduce all-cause hospitalizations and overall medical costs, according to a new analysis.

The Healio Editors compiled the most-read news in pulmonology posted in August.

Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic thromboembolic pulmonary hypertension, according to results published in European Respiratory Journal.

SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.

The Healio Editors compiled the most-read pulmonary hypertension news published in 2021.

The REVEAL Lite 2 risk assessment tool is prognostic of long-term outcomes in patients with pulmonary arterial hypertension and also detected response to treatment, a presenter said at the CHEST Annual Meeting.

This week, Pfizer says a third dose of the vaccine boosts protection, even against the delta variant; US News and World Report ranks Mayo Clinic number 1 for pulmonology and lung surgery; the FDA approves IV selexipag for adults with PAH; and more.

In a post hoc analysis of the GRIPHON study, patients with newly diagnosed pulmonary arterial hypertension had a worse prognosis compared with those with a longer time from diagnosis.